Deal Making

Featured on Deal Making

Lilly going bigger on obesity with Versanis buy
Deal-Making
Lilly going bigger on obesity with Versanis buyLilly going bigger on obesity with Versanis buy

Eli Lilly will pay up to $1.925 billion to acquire biotech Versanis, adding its Phase II obesity candidate bimagrumab to its pipeline.

More from Deal Making